ArticleJournal of bone oncology2025
Evaluation of Zimmer® segmental distal femur mega-prostheses: Patient survival, surgical outcomes and functional outcome.
Article in Journal of bone oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Modular knee mega-prostheses are considered the method of choice for reconstruction after resection of malignant bone lesions around the knee. The available literature evaluating Zimmer® Segmental mega-prostheses is sparse. The purpose of the present study is to evaluate the use of Zimmer® Segmental mega-prosthesis for reconstruction of the distal femur, following the resection of bone malignancies and aggressive benign bone tumors. Material and Methods: A retrospective study including 59 consecutive patients (F/M = 35/24), mean age 58 (range 17-86) who underwent reconstructions of the distal femur due to malignant bone lesions (n = 51) or aggressive benign bone tumors (n = 8) from 2017 to 2022. All reconstructions were performed with the most recent Zimmer® Segmental System with the XT Distal Femoral Component. Kaplan-Meier survival analysis was used for evaluation of overall survival. Competing risk analysis was used for assessing cumulative incidence of revision and amputation. Patients were followed until death or end of study (December 31st, 2024). Functional outcome and quality of life was evaluated with Musculoskeletal Tumor Society Score (MSTS), European quality of life - 5 Dimensions score (EQ 5D) and Oxford Knee Score (OKS). Results: Twenty-eight (n = 28) patients were alive at follow-up. Overall survival after 5-year was 44 % (CI95%: 30-58 %). The risk of implant failure after 1 and 5 years was 8 % (95 %CI 1-16 %) and 12 % (95 %CI 4-20 %) respectively. One patient (2 %) underwent amputation. Mean MSTS score was 17 (57 %) (range 3-30). Mean EQ 5D index score was 0.88 and mean EQ-5D VAS score was 68. OKS demonstrated a mean score of 31. Conclusion: The Zimmer® Segmental mega-prosthesis in distal femur reconstruction with the improved XT femoral component, demonstrated a relatively low risk of implant failure, and a low risk of amputation. The risk of implant failure was higher among patients who underwent radiotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.